Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia

Abstract

IntroductionMutations in the breakpoint cluster region-Abelson murine leukemia 1 gene are the leading cause of resistance to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Mutations have been detected throughout the extension of the kinase domain of this gene and it is important to investigate their positions because there may be a difference in clinical relevance.ObjectiveTo evaluate mutations in the transcripts of the BCR-ABL1 gene in Brazilian patients with chronic myeloid leukemia under tyrosine kinase inhibitor treatment in the Hospital de Clínicas of the Universidade Federal do Paraná.MethodsThis retrospective observational cross-sectional study analyzed mutation data of BCR-ABL1 gene transcripts. Three hundred and thirty peripheral blood samples from 193 patients were evaluated with the search for mutations being achieved by Sanger sequencing.ResultsSixteen mutation types were identified in 48/193 (24.87%) patients with T315I (20.83%) being the most common. Furthermore, four polymorphisms (T240T, K247R, E275E and Y275Y) were identified. The highest incidence of mutations (19/53: 35.85%) occurred in the P-loop of the tyrosine kinase domain, whereas no mutation was found in the A-loop. In 43/48 (89.58%) patients only one mutation was found and more than one mutation was found in 5/48 (10.42%). The simultaneous presence of two mutations (E189G/V299L and E255K/T315I) was observed in 2/5 patients while the different mutations were seen in sequential samples of the other three patients (Y253Y/T315I, T315I/E255K and E255K/T315I).ConclusionsThis molecular characterization contributed to the identification of the resistance profile to tyrosine kinase inhibitors in Brazilian patients, thus enabling the use of adequate therapeutic strategies in a timely manner.

Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study

“…A recent Chinese report evaluated ABL1 mutation in a sub-cohort of 175 patients who exhibited TKI resistance (first-line TKIs: 164 patients, 93.7%; second-line TKIs: 11 patients, 6.3%) and found that just 54 harbored mutations in the kinase domain, with there being a greater frequency of T315I and E255K [ 51 ]. In a Brazilian survey, 48 out of 193 CML patients showed mutations in ABL1 , with the highest frequencies found for T315I and G250E (20.83% and 14.5%, respectively) [ 52 ]. Another Brazilian report showed no ABL1 mutations in 58 CML patients undergoing treatment with imatinib who showed a suboptimal response [ 53 ].…”

Implementation of pharmacogenetics for treatment of patients with acute lymphoblastic leukemia

“…In 193 patients, two simultaneous mutations (E189G/V299L and E255K/ T315I) were observed in 2/5 of patients while other mutations were found in sequential samples of the other three patients (Y253Y/T315I, T315I/E255K and E255K/ T315I). This molecular characterization contributes to the identification of resistance profile to TKI inhibition in Brazilian patients (Costa et al 2018). Tanasi et al 2019 dentified the ABL-class fusion was identified at initial diagnosis work up and TKI was introduced during front line treatment.…”